{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,5]],"date-time":"2026-11-05T20:40:44Z","timestamp":1793911244481,"version":"4.8.0"},"reference-count":26,"publisher":"BMJ","issue":"4","content-domain":{"domain":["bmj.com"],"crossmark-restriction":true},"short-container-title":["BMJ Open"],"accepted":{"date-parts":[[2017,3,9]]},"published-print":{"date-parts":[[2017,4]]},"abstract":"<jats:sec><jats:title>Objective<\/jats:title><jats:p>The aim of this study was to estimate the proportion of rubella disease in a measles case-based surveillance in Cameroon prior to rubella vaccine introduction into the national immunisation programme.<\/jats:p><\/jats:sec><jats:sec><jats:title>Design<\/jats:title><jats:p>This was a cross-sectional study for rubella infection in Cameroon for the period 2008 to 2014.<\/jats:p><\/jats:sec><jats:sec><jats:title>Setting<\/jats:title><jats:p>Patients suspected with measles from the 10 regions of Cameroon were recruited according to the WHO measles case definition and were tested for rubella IgM antibodies accompanied with the case report\/investigation forms.<\/jats:p><\/jats:sec><jats:sec><jats:title>Participants<\/jats:title><jats:p>All persons with rash and fever within 14 days of onset of rash according to the standard WHO African Regional Office (WHO\/AFRO) case definition for a suspected measles case.<\/jats:p><\/jats:sec><jats:sec><jats:title>Outcome measures<\/jats:title><jats:p>Descriptive analyses and simple logistic regressions were performed. OR were estimated.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>A total of 9907 serum samples from people with fever and rash were received in the laboratory from 2008 to 2014. A total of 7489 (75.59%) measles-negative samples were tested for rubella; 699 (9.3%) were positive for rubella IgM antibodies. Logistic regression analysis was done using IgM antibodies detection as the outcome variable. Age, sex and setting were explanatory variables. Logistic regression analysis revealed that, comparing the proportion of rubella IgM seropositivity status by age, the association to a positive rubella IgM increased with age from 1 to 4 years (OR 7.11; 95% CI 4.35 to 12.41; p&lt;0.0001), through 5 to 9 years (OR 13.07; 95% CI 7.93 to 22.93; p&lt;0.001), to 10 to 14 years of age (OR 13.86; 95% CI 8.06 to 25.12; p&lt;0.001). Persons aged \u226515 years were also more likely to have rubella infection than children under one (OR 3.69; 95% CI 1.85 to 7.48; p=0.0001). There were also significant associations with sex, with males being less associated to a positive rubella serology than females (OR 1.33; 95% CI 1.14 to 1.56; p=0.0001). No statistically significant difference in proportion of rubella cases was observed between urban and rural populations (OR 1.11; 95% CI 0.94 to 1.31; p=0.208).<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusions<\/jats:title><jats:p>This study reveals that rubella virus circulates in Cameroon, with important number of cases in children under 15 years. This finding supports the planned introduction of rubella-containing vaccines into the Expanded Program on Immunization.<\/jats:p><\/jats:sec>","DOI":"10.1136\/bmjopen-2016-012959","type":"journal-article","created":{"date-parts":[[2017,4,8]],"date-time":"2017-04-08T00:10:33Z","timestamp":1491610233000},"page":"e012959","update-policy":"https:\/\/doi.org\/10.1136\/crossmarkpolicy","source":"Crossref","is-referenced-by-count":17,"title":["Epidemiology of rubella infection in Cameroon: a 7-year experience of measles and rubella case-based surveillance, 2008\u20132014"],"prefix":"10.1136","volume":"7","author":[{"given":"Marcellin","family":"Nimpa Mengouo","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Valantine Ngum","family":"Ndze","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Frangy","family":"Baonga","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marie","family":"Kobela","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Charles Shey","family":"Wiysonge","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"239","published-online":{"date-parts":[[2017,4,7]]},"reference":[{"key":"2024051611054908000_7.4.e012959.1","unstructured":"McLean H , Redd S , Abernathy E , et al . VPD surveillance manual, fifth edition, 2012. https:\/\/www.cdc.gov\/vaccines\/pubs\/surv-manual\/chpt14-rubella.pdf"},{"key":"2024051611054908000_7.4.e012959.2","doi-asserted-by":"publisher","DOI":"10.1001\/jama.1965.03080210019005"},{"key":"2024051611054908000_7.4.e012959.3","doi-asserted-by":"crossref","first-page":"1362","DOI":"10.1056\/NEJM196512162732504","article-title":"Purpura in congenital and acquired rubella","volume":"273","author":"Bayer","year":"1965","journal-title":"N Engl J Med"},{"key":"2024051611054908000_7.4.e012959.4","doi-asserted-by":"crossref","unstructured":"Cooper LZ , Alford, C.A. , Rubella. In Remington JS , ed. Infectious diseases of the fetus and newborn infant. 6th edn. Philadelphia: Elsevier, Saunders, 2006:894\u2013926.","DOI":"10.1016\/B0-72-160537-0\/50030-X"},{"key":"2024051611054908000_7.4.e012959.5","first-page":"301","article-title":"Rubella vaccines: WHO position paper","volume":"29","author":"World Health Organisation","year":"2011","journal-title":"Weekly epidemiological record"},{"key":"2024051611054908000_7.4.e012959.6","doi-asserted-by":"publisher","DOI":"10.1093\/infdis\/jir107"},{"key":"2024051611054908000_7.4.e012959.7","unstructured":"WHO. Global measles and rubella strategic plan: 2012\u20132020, 2012. http:\/\/apps.who.int\/iris\/bitstream\/10665\/44855\/1\/9789241503396_eng.pdf"},{"key":"2024051611054908000_7.4.e012959.8","doi-asserted-by":"publisher","DOI":"10.1186\/1471-2458-13-406"},{"key":"2024051611054908000_7.4.e012959.9","unstructured":"WHO. Introducing rubella vaccine into national immunization programmes, a step-by-step guide. WHO\/IVB\/15.07 2015 http:\/\/apps.who.int\/iris\/bitstream\/10665\/184174\/1\/9789241549370_eng.pdf"},{"key":"2024051611054908000_7.4.e012959.10","unstructured":"Bureau Central des Recensements et des Etudes de Population (BUCREP). Etat et structures de la population du\u00a0Cameroun; recensement 2005. http:\/\/www.statistics-cameroon.org\/downloads\/Rapport_de_presentation_3_RGPH.pdf"},{"key":"2024051611054908000_7.4.e012959.11","unstructured":"Statistique INdela (INS). Enqu\u00eate d\u00e9mographique et de sant\u00e9 et \u00e0 indicateurs multiples (EDS-MICS 2011), Septembre 2012. http:\/\/www.cnls.cm\/docs\/Rapport_EDS_2011_au_Cameroun.pdf"},{"key":"2024051611054908000_7.4.e012959.12","unstructured":"WHO Regional Office for Africa. Guidelines for measles surveillance, revised December 2011."},{"key":"2024051611054908000_7.4.e012959.13","doi-asserted-by":"publisher","DOI":"10.1093\/infdis\/jir120"},{"key":"2024051611054908000_7.4.e012959.14","doi-asserted-by":"crossref","first-page":"294","DOI":"10.1186\/s12889-015-1642-4","article-title":"Trends of rubella incidence during a 5-year period of case based surveillance in Zimbabwe","volume":"15","author":"Chimhuya","year":"2015","journal-title":"BMC Public Health"},{"key":"2024051611054908000_7.4.e012959.15","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1186\/1471-2393-14-95","article-title":"Sero-positivity rate of rubella and associated factors among pregnant women attending antenatal care in Mwanza, Tanzania","volume":"14","author":"Mwambe","year":"2014","journal-title":"BMC Pregnancy Childbirth"},{"key":"2024051611054908000_7.4.e012959.16","doi-asserted-by":"crossref","first-page":"244","DOI":"10.1186\/1743-422X-8-244","article-title":"Sero-survey of rubella IgM antibodies among children in Jos, Nigeria","volume":"8","author":"Junaid","year":"2011","journal-title":"Virol J"},{"key":"2024051611054908000_7.4.e012959.17","doi-asserted-by":"crossref","first-page":"245","DOI":"10.4314\/wajm.v23i3.28131","article-title":"Prevalence of rubella antibody in pregnant women in Ibadan, Nigeria","volume":"23","author":"Bamgboye","year":"2004","journal-title":"West Afr J Med"},{"key":"2024051611054908000_7.4.e012959.18","first-page":"10","article-title":"Survey of the sero-prevalence of IgM antibodies in pregnant women infected with rubella virus","volume":"3","author":"Ogbonnaya","year":"2012","journal-title":"J Biotechnol Pharm Res"},{"key":"2024051611054908000_7.4.e012959.19","first-page":"69","article-title":"Serologic survey of specific rubella virus IgM in the sera of pregnant women in Makurdi, Benue State, Nigeria","volume":"13","author":"Pennap","year":"2009","journal-title":"Afr J Reprod Health"},{"key":"2024051611054908000_7.4.e012959.20","doi-asserted-by":"crossref","first-page":"140","DOI":"10.4103\/1119-3077.84002","article-title":"Seroprevalence survey of rubella infection in pregnancy at the University of Benin Teaching Hospital, Benin City, Nigeria","volume":"14","author":"Onakewhor","year":"2011","journal-title":"Niger J Clin Pract"},{"key":"2024051611054908000_7.4.e012959.21","first-page":"55","article-title":"Control of rubella and congenital rubella syndrome (CRS) in developing countries, part 1: burden of disease from CRS","volume":"75","author":"Cutts","year":"1997","journal-title":"Bull World Health Organ"},{"key":"2024051611054908000_7.4.e012959.22","first-page":"1","article-title":"Identification of ocular and auditory manifestations of congenital rubella syndrome in Mbingo","volume":"2014","author":"Jivraj","year":"2014","journal-title":"Int J Telemed Appl"},{"key":"2024051611054908000_7.4.e012959.23","unstructured":"Castillo-Salgado C . Case definitions: measles and rubella.\u00a0Epidemiological Bulletin \/ PAHO. 1999;20:10. accessed http:\/\/www1.paho.org\/english\/sha\/EB_v20n3.pdf"},{"key":"2024051611054908000_7.4.e012959.24","unstructured":"WHO. Surveillance guidelines for measles, rubella and congenital rubella syndrome in the WHO European Region. Copenhagen: WHO Regional Office for Europe, 2012. http:\/\/www.euro.who.int\/__data\/assets\/pdf_file\/0018\/79020\/e93035-2013.pdf"},{"key":"2024051611054908000_7.4.e012959.25","doi-asserted-by":"crossref","first-page":"17","DOI":"10.2807\/esm.09.04.00461-en","article-title":"Epidemiology of rubella and congenital rubella syndrome in Greece, 1994-2003","volume":"9","author":"Panagiotopoulos","year":"2004","journal-title":"Euro Surveill"},{"key":"2024051611054908000_7.4.e012959.26","first-page":"69","article-title":"Control of rubella and congenital rubella syndrome (CRS) in developing countries, part 2: vaccination against rubella","volume":"75","author":"Robertson","year":"1997","journal-title":"Bull World Health Organ"}],"container-title":["BMJ Open"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1136\/bmjopen-2016-012959","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,5,16]],"date-time":"2024-05-16T18:32:40Z","timestamp":1715884360000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmjopen.bmj.com\/lookup\/doi\/10.1136\/bmjopen-2016-012959"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,4]]},"references-count":26,"journal-issue":{"issue":"4","published-online":{"date-parts":[[2017,4,7]]},"published-print":{"date-parts":[[2017,4]]}},"alternative-id":["10.1136\/bmjopen-2016-012959"],"URL":"https:\/\/doi.org\/10.1136\/bmjopen-2016-012959","relation":{},"ISSN":["2044-6055","2044-6055"],"issn-type":[{"value":"2044-6055","type":"print"},{"value":"2044-6055","type":"electronic"}],"subject":[],"published":{"date-parts":[[2017,4]]}}}